Tackling Psoriasis and Overweight/Obesity Together
A phase 3b clinical trial, TOGETHER-PsO, found that combining the drugs ixekizumab and tirzepatide effectively treats both moderate to severe psoriasis and obesity. The study suggests that addressing these conditions simultaneously improves patient outcomes.
Why it matters
Given the high comorbidity between psoriasis and obesity, this dual-treatment approach could significantly improve the quality of life and long-term health outcomes for a large patient population.
Tackling Psoriasis and Overweight/Obesity Together | Docwire News
The report summarizes medical trial findings and expert commentary in a neutral, factual manner.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in